Johns Hopkins Study: Teen Cannabis Use Disorder Raises Schizophrenia Risk by 52%

A major new study from Johns Hopkins University has found that teenagers who develop cannabis use disorder face dramatically elevated risks of psychiatric diagnoses — including a 52% higher relative risk of schizophrenia — compared to adolescents with other substance use disorders. The findings, published in The American Journal of Psychiatry in March 2026, add important nuance to the ongoing national debate about cannabis legalization and youth access.

The research arrives at a pivotal moment: cannabis is now legally accessible to adults in the majority of U.S. states, and the federal government is actively working to reschedule marijuana from Schedule I. Understanding the specific risks for the youngest users has never been more urgent.

What the Study Found

Led by researchers at the Johns Hopkins Bloomberg School of Public Health, the study analyzed nearly 700,000 U.S. medical records, including 691,806 patient records and a separate pediatric dataset of 49,586 patients under age 17 with substance use disorders.

The core comparison was between young patients diagnosed with cannabis use disorder and those diagnosed with other substance use disorders. Among those aged 17 and under, the relative risk of specific psychiatric diagnoses was strikingly elevated for those in the cannabis use disorder group:

• Schizophrenia: 52% higher relative risk
• Recurrent major depression: 30% higher relative risk
• Anxiety disorders: 21% higher relative risk

These are relative risk increases — meaning they describe how much more likely a teen with cannabis use disorder is to receive these diagnoses compared to a teen with a different substance use disorder, not compared to the general population. The absolute numbers are still meaningful, but the relative framing is important context.

The Age Divide: Why Teens and Adults Respond Differently

One of the most striking findings was how sharply the risk profile differed by age. While teens with cannabis use disorder showed elevated psychiatric risk, adults with cannabis use disorder in the study were significantly less likely to develop psychiatric disorders compared to adults with other substance use disorders.

This divergence supports a growing body of neuroscientific research suggesting that cannabis affects the developing brain differently than the mature adult brain. The human brain is not fully developed until roughly age 25, and cannabis's interaction with the endocannabinoid system — which plays a critical role in brain development — may be fundamentally different during adolescence.

The researchers noted that much of their interest in conducting the study was prompted by the recent wave of state-level recreational legalization, including Maryland's legalization in 2023. "We wanted to understand cannabis-related psychotic disorders in the context of other substance-related psychotic disorders," the team explained. "The age difference is striking and demands serious attention from policymakers and clinicians."

The Causation Question

Researchers are careful not to claim causation definitively. Correlation studies of this nature cannot rule out that teens with underlying psychiatric vulnerabilities are more likely to develop cannabis use disorder in the first place — a confounding factor known as the "self-medication hypothesis."

However, the biological plausibility of cannabis causing psychiatric harm in developing brains is strong. The endocannabinoid system modulates dopamine signaling, which is central to schizophrenia risk. THC's disruption of this system during adolescent brain development could, in theory, trigger latent psychiatric vulnerabilities that might otherwise have remained dormant or emerged later with less severity.

The direction of causality is likely bidirectional — psychiatric risk can lead to cannabis use disorder, and cannabis use disorder can exacerbate or trigger psychiatric conditions. What the Johns Hopkins study adds is evidence of how much more pronounced this bidirectional risk is during adolescence than in adulthood.

Context: How This Fits Into the Broader Research Picture

The Johns Hopkins study is one of several significant cannabis-and-mental-health findings published in early 2026. In March, a landmark systematic review published in The Lancet Psychiatry analyzed 54 randomized controlled trials and found no evidence that medicinal cannabis effectively treats anxiety, depression, or PTSD in adults. In February, a large Canadian study of 35,000 participants found that regular cannabis users (two or more times per week) were about five times more likely to report anxiety, depression, or suicidal ideation.

Taken together, these studies paint a more cautious picture of cannabis and mental health than the commercial cannabis industry typically promotes. They don't argue for prohibition — the harms of criminalization are also well-documented — but they do make a strong case for age restrictions, public education, and robust screening programs.

What This Means for Parents, Clinicians, and Policymakers

The findings carry several practical implications. For parents, the study reinforces the importance of having direct, factual conversations with teenagers about cannabis risks — particularly the psychiatric ones, which are less visible and immediate than, say, the dangers of drunk driving but potentially more lasting.

For clinicians, the study supports routine screening for cannabis use disorder in adolescent patients presenting with early psychiatric symptoms. Early intervention in cannabis use disorder during teenage years could theoretically reduce downstream psychiatric diagnosis rates, though more research is needed to confirm this.

For policymakers, the age divide in risk profiles strengthens the scientific case for strict age verification at dispensaries and for public health campaigns specifically targeting teen cannabis use. Several states have recently tightened enforcement around underage sales following similar findings; the Johns Hopkins study gives those efforts additional empirical backing.

What the Study Does Not Say

It's equally important to note what this research doesn't claim. It does not argue that moderate or occasional adult cannabis use causes schizophrenia. It does not call for recriminalization of cannabis. It does not suggest that the majority of teens who try cannabis will develop psychiatric disorders — most will not.

What it does say is that adolescents who develop a diagnosable use disorder face substantially elevated psychiatric risk compared to same-age peers with other substance use disorders, and that this risk pattern doesn't replicate in adults. That's a clinically meaningful finding with real-world implications for how we regulate, discuss, and respond to cannabis use among young people.

Key Takeaways

• A Johns Hopkins study published in The American Journal of Psychiatry found teens with cannabis use disorder face 52% higher relative schizophrenia risk versus teens with other substance use disorders.
• Additional elevated risks include 30% higher odds of recurrent major depression and 21% higher odds of anxiety disorders.
• The risk profile reverses in adults, who showed lower psychiatric risk with cannabis use disorder than other substance use disorders — suggesting the developing brain is uniquely vulnerable.
• The findings do not establish definitive causation but support stricter youth cannabis access controls and clinical screening.

Explore cannabis science, dispensary guides, and community resources at Budpedia.